Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 1604 • 2019 ACR/ARP Annual Meeting
The Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹, Erik Barr ² and Laurence Magder ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in systemic lupus erythematosus (SLE). Yet, the "traditional" cardiovascular risk equations (such…
Abstract Number: 1763 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, Eric Morand ², Ian Bruce ³, Susan Manzi ⁴, Kenneth Kalunian ⁵, Edward Vital ⁶, Theresa Lawrence-Ford ⁷, Ramesh Gupta ⁸, Falk Hiepe ⁹, Mittermayer Santiago ¹⁰, Philip Brohawn ¹¹, Anna Berglind ¹² and Raj Tummala ¹³, ¹Zucker School of Medicine at Hofstra/Northwell, New York, NY, ²Monash University, Melbourne, Victoria, Australia, ³University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁴Allegheny Health Network, Pittsburg, PA, ⁵Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁶University of Leeds, Leeds, United Kingdom, ⁷North Georgia Rheumatology, Lawrenceville, GA, ⁸Baptist Memorial Hospital-Memphis, Memphis, TN, ⁹Charité University Hospital Berlin, Berlin, Germany, ¹⁰Bahiana School of Medicine and Public Health, Bahia, Brazil, ¹¹AstraZeneca, Gaithersburg, MD, ¹²AstraZeneca, Gothenburg, Sweden, ¹³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the type I…
Abstract Number: 2026 • 2019 ACR/ARP Annual Meeting
MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27
Daiga Kishimoto¹, Ryusuke Yoshimi ¹, Yosuke Kunishita ¹, Yumiko Sugiyama ², Takaaki Komiya ¹, Natsuki Sakurai ³, Reikou Kamiyama ¹, Yohei Kirino ⁴ and Hideaki Nakajima ⁴, ¹Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama City, Japan, ⁴Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Type Ⅰ interferons (IFN) contribute to antiviral innate immune responses. Upon viral infection, pattern recognition receptors trigger TANK-binding kinase 1 (TBK1) activation and lead…
Abstract Number: 2293 • 2019 ACR/ARP Annual Meeting
Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy
Mitali Sen¹, Anu Kurl ¹, Tejal Vashi ² and Arezou Khosroshahi ¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age. Cyclophosphamide, an alkylating agent, labelled category D for pregnancy, is used for induction in…
Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Sooyeon Kwon¹, Jessica Farrell ², Sarfaraz Hasni ³ and Shubhasree Banerjee ², ¹The Center For Rheumatology, Loudonville, NY, ²The Center for Rheumatology, LLC, Albany, NY, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…
Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Goh Murayama¹, Asako Chiba ², Tomohiro Mizuno ³, Atsushi Nomura ², Taiga Kuga ⁴, HIrofumi Amano ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2882 • 2019 ACR/ARP Annual Meeting
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Vera Golder¹, Molla Huq ², Rangi Kandane-Rathnayake ³, Worawit Louthrenoo ⁴, Shue Fen Luo ⁵, Yeong-Jian Wu ⁵, Aisha Lateef ⁶, Sargunan Sockalingam ⁷, Sandra Navarra ⁸, Leonid Zamora ⁹, Laniyati Hamijoyo ¹⁰, Yasuhiro Katsumata ¹¹, Masayoshi Harigai ¹², Madelynn Chan ¹³, Sean O'Neill ¹⁴, Fiona Goldblatt ¹⁵, Chak Sing Lau ¹⁶, Zhanguo Li ¹⁷, Alberta Hoi ¹⁸, Mandana Nikpour ¹⁹ and Eric Morand ¹, ¹Monash University, Melbourne, Victoria, Australia, ²University of Melbourne, Melbourne, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University Hospital, Chiang Mai, Thailand, ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas Hospital, Manila, Philippines, ⁹Santo Tomas Hospital, Manila, Philippines, ¹⁰Padjadjaran University, Bandung, Indonesia, ¹¹Tokyo Women's University, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴University of New South Wales, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁹St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated…
Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Savino Sciascia¹, Massimo Radin ², Irene Cecchi ², Maria Laura Bertolaccini ³, Tiziana Bertero ², Elena Rubini ², Antonella Vaccarino ², Mario Bazzan ², Osvaldo Giachino ², Simone Baldovino ², Daniela Rossi ², Giulio Mengozzi ² and Dario Roccatello ², ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…
Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Amanda Eudy¹, Jennifer Rogers ¹, Raeann Whitney ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Rebecca Sadun ¹, Kai Sun ¹ and Megan Clowse ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…
Abstract Number: 940 • 2019 ACR/ARP Annual Meeting
Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis
Konstantinos Tselios¹, Laura Wakani ², Dafna Gladman ³, Jiandong Su ⁴ and Murray Urowitz ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University Health Network, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Most randomized controlled trials (RCTs) with biologic medicines in systemic lupus erythematosus (SLE) failed to reach their respective end-points with the rates of the…
Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Melinda Kedves¹, Fruzsina Kósa ², Péter Takács ², Péter Kunovszki ², Jennifer Lofland ³ and György Nagy ⁴, ¹Hospital of Bács-Kiskun County, Department of Rheumatology, Kecskemét, Bacs-Kiskun, Hungary, ²Janssen, GCSO, Budapest, Budapest, Hungary, ³Janssen Scientific Affairs, LLC, Spring House, PA, ⁴Buda Hospital of the Hospitaller Order of Saint John of God, Department of Rheumatology, Budapest, Budapest, Hungary
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 1606 • 2019 ACR/ARP Annual Meeting
Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Smoking and African- American ethnicity are risk factors for systemic lupus erythematosus (SLE). Smoking has been associated with increased prevalence of SLE, increased disease…
Abstract Number: 1767 • 2019 ACR/ARP Annual Meeting
Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Matteo Cesaroni¹, Loqmane Seridi ¹, Jarrat Jordan ¹, Kristen Sweet ¹, Keying Ma ¹, Carol Franks ¹, Jessica Schreiter ¹, Peter Lipsky ², Ronald van Vollenhoven ³, Bevra Hahn ⁴, Shawn Rose ¹, Frédéric Baribaud ¹, Matthew Loza ¹, Kim Campbell ¹ and George Tsokos ⁵, ¹Janssen Research & Development, LLC, Spring House, PA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴University of California, Los Angeles, CA, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease that causes progressive organ damage. The cytokines type I interferon (IFN-I), IL-12 and IL-23 have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].